Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 1
2005 1
2006 5
2007 13
2008 6
2009 1
2010 4
2011 5
2012 4
2013 16
2014 21
2015 23
2016 33
2017 37
2018 38
2019 35
2020 54
2021 44
2022 40
2023 46
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

362 results

Results by year

Filters applied: . Clear all
Page 1
Reply by Author.
St-Laurent MP, Acland G, Hamilton SN, Hamm J, Sunderland K, Black PC, McKenzie M, Keyes M, Miller S, Gleave ME, Tyldesley S. St-Laurent MP, et al. Among authors: black pc. J Urol. 2024 May 7:101097JU0000000000004006. doi: 10.1097/JU.0000000000004006. Online ahead of print. J Urol. 2024. PMID: 38713553 No abstract available.
Alignment of molecular subtypes across multiple bladder cancer subtyping classifiers.
Reike MJ, de Jong JJ, Bismar TA, Boorjian SA, Mian OY, Wright JL, Dall'Era MA, Kaimakliotis HZ, Lotan Y, Boormans JL, Black PC, Gibb EA. Reike MJ, et al. Among authors: black pc. Urol Oncol. 2024 Jun;42(6):177.e5-177.e14. doi: 10.1016/j.urolonc.2024.01.027. Epub 2024 Mar 12. Urol Oncol. 2024. PMID: 38480079
The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer.
von Deimling M, Mertens LS, Furrer M, Li R, Tendijck GAH, Taylor J, Crocetto F, Maas M, Mari A, Pichler R, Moschini M, Tully KH, D'Andrea D, Laukhtina E, Del Giudice F, Marcq G, Velev M, Gallioli A, Albisinni S, Mori K, Khanna A, Rink M, Fisch M, Minervini A, Black PC, Lotan Y, Spiess PE, Kiss B, Shariat SF, Pradere B; CLIPOLY Study Group Collaborators. von Deimling M, et al. Among authors: black pc. BJU Int. 2024 Mar 12. doi: 10.1111/bju.16319. Online ahead of print. BJU Int. 2024. PMID: 38470089 Free article.
Benefit of Neoadjuvant Cisplatin-based Chemotherapy for Invasive Bladder Cancer Patients Treated with Radiation-based Therapy in a Real-world Setting: An Inverse Probability Treatment Weighted Analysis.
Kool R, Dragomir A, Kulkarni GS, Marcq G, Breau RH, Kim M, Busca I, Abdi H, Dawidek M, Uy M, Fervaha G, Cury FL, Alimohamed N, Izawa J, Jeldres C, Rendon R, Shayegan B, Siemens R, Black PC, Kassouf W. Kool R, et al. Among authors: black pc. Eur Urol Oncol. 2024 Feb 6:S2588-9311(24)00040-3. doi: 10.1016/j.euo.2024.01.014. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38326142
Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer.
Galsky MD, Guan X, Rishipathak D, Rapaport AS, Shehata HM, Banchereau R, Yuen K, Varfolomeev E, Hu R, Han CJ, Li H, Liang Y, Vucic D, Wang L, Zhu J, Yu H, Herbst RH, Hajaj E, Kiner E, Bamias A, De Santis M, Davis ID, Arranz JÁ, Kikuchi E, Bernhard S, Williams P, Lee C, Mellman I, Sanjabi S, Johnston R, Black PC, Grande E, Mariathasan S. Galsky MD, et al. Among authors: black pc. Cell Rep Med. 2024 Feb 20;5(2):101393. doi: 10.1016/j.xcrm.2024.101393. Epub 2024 Jan 26. Cell Rep Med. 2024. PMID: 38280376 Free PMC article. Clinical Trial.
362 results